User login
Key clinical point: Androgen-signaling inhibitors (ASIs) are associated with significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) with luminal tumor subtype.
Major finding: ASI treatment was associated with an improved overall survival in patients with luminal tumors (hazard ratio [HR], 0.27; P < .001), but not in those with basal tumors (HR, 0.62; P = .07).
Study details: A retrospective study of 4 patient cohorts (n=634) with mCRPC.
Disclosures: This study was funded by grants from the Department of Defense, Stand Up To Cancer-Prostate Cancer Foundation, Prostate Cancer Foundation, Movember Foundation, UCSF Benioff, Swedish Research Council, National Cancer Institute, and University of Wisconsin Carbone Cancer Center. The authors received consulting/advisory fees, research funding, and grants outside this work. Some authors reported pending patents and/or being employed with pharmaceutical companies.
Source: Aggarwal R et al. JAMA Oncol. 2021 Sep 23. doi: 10.1001/jamaoncol.2021.3987.
Key clinical point: Androgen-signaling inhibitors (ASIs) are associated with significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) with luminal tumor subtype.
Major finding: ASI treatment was associated with an improved overall survival in patients with luminal tumors (hazard ratio [HR], 0.27; P < .001), but not in those with basal tumors (HR, 0.62; P = .07).
Study details: A retrospective study of 4 patient cohorts (n=634) with mCRPC.
Disclosures: This study was funded by grants from the Department of Defense, Stand Up To Cancer-Prostate Cancer Foundation, Prostate Cancer Foundation, Movember Foundation, UCSF Benioff, Swedish Research Council, National Cancer Institute, and University of Wisconsin Carbone Cancer Center. The authors received consulting/advisory fees, research funding, and grants outside this work. Some authors reported pending patents and/or being employed with pharmaceutical companies.
Source: Aggarwal R et al. JAMA Oncol. 2021 Sep 23. doi: 10.1001/jamaoncol.2021.3987.
Key clinical point: Androgen-signaling inhibitors (ASIs) are associated with significant survival benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) with luminal tumor subtype.
Major finding: ASI treatment was associated with an improved overall survival in patients with luminal tumors (hazard ratio [HR], 0.27; P < .001), but not in those with basal tumors (HR, 0.62; P = .07).
Study details: A retrospective study of 4 patient cohorts (n=634) with mCRPC.
Disclosures: This study was funded by grants from the Department of Defense, Stand Up To Cancer-Prostate Cancer Foundation, Prostate Cancer Foundation, Movember Foundation, UCSF Benioff, Swedish Research Council, National Cancer Institute, and University of Wisconsin Carbone Cancer Center. The authors received consulting/advisory fees, research funding, and grants outside this work. Some authors reported pending patents and/or being employed with pharmaceutical companies.
Source: Aggarwal R et al. JAMA Oncol. 2021 Sep 23. doi: 10.1001/jamaoncol.2021.3987.